Skip to main content

Advertisement

SpringerLink
Log in

Cancer immunotherapy

Myeloma evades T cell-engaging therapies

  • News & Views
  • Published:

From Nature Cancer

View current issue Submit your manuscript

Chimeric antigen receptor T cells and T cell-redirecting bispecific antibody therapies are changing the landscape of myeloma therapy. Two studies investigate the genetic and epigenetic resistance mechanisms that lead to relapse in patients receiving T cell-engaging therapies targeting B cell maturation antigen (BCMA) and GPRC5D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Mechanisms of resistance to CAR T cell and T cell-redirecting bsAb therapies for the treatment of relapsed/refractory multiple myeloma.

References

  1. Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Berdeja, J. G. et al. Lancet 398, 314–324 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. San-Miguel, J. et al. N. Engl. J. Med. 389, 335–347 (2023).

    Article  CAS  PubMed  Google Scholar 

  4. Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rodriguez-Otero, P. et al. N. Engl. J. Med. 388, 1002–1014 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Mailankody, S. et al. N. Engl. J. Med. 387, 1196–1206 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chari, A. et al. N. Engl. J. Med. 387, 2232–2244 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Holstein, S. A., Grant, S. J. & Wildes, T. M. J. Clin. Oncol. https://doi.org/10.1200/JCO.23.00512 (2023).

    Article  PubMed  Google Scholar 

  9. Lee, H. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02491-5 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Derrien, J. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00625-9 (2023).

    Article  PubMed  Google Scholar 

  11. Bird, S. & Pawlyn, C. Blood 142, 131–140 (2023).

    CAS  PubMed  Google Scholar 

  12. Truger, M. S. et al. Blood Adv. 5, 3794–3798 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Da Vià, M. C. et al. Nat. Med. 27, 616–619 (2021).

    Article  PubMed  Google Scholar 

  14. Samur, M. K. et al. Nat. Commun. 12, 868 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Friedrich, M. J. et al. Cancer Cell 41, 711–725.e6 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, CCUN, Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain

    Bruno Paiva & Jesús F. San-Miguel

Authors
  1. Bruno Paiva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús F. San-Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Paiva.

Ethics declarations

Competing interests

B.P. reports consultancy fees from BMS, GSK, Janssen, Sanofi and Takeda; research funding from BMS, GSK, Roche and Sanofi; and honoraria from Adaptive, Amgen, Becton Dickinson, BMS-Celgene, GSK, Janssen, Sanofi and Roche. J.F.S.-M. reports consultancy fees from Abbvie, Amgen, BMS, Celgene, Roche, GSK, Janssen, Karyopharm, Merck, Novartis, Sanofi and Takeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paiva, B., San-Miguel, J.F. Myeloma evades T cell-engaging therapies. Nat Cancer 4, 1534–1535 (2023). https://doi.org/10.1038/s43018-023-00637-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00637-5

  • Springer Nature America, Inc.

Search

Navigation